Benzinga - by Piero Cingari, Benzinga Staff Writer. Investors are always on the lookout for untapped opportunities, especially in stocks that have been heavily discounted and now...
Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) released clinical data for vepdegestrant (ARV-471) in combination with palbociclib (IBRANCE). Interim results from the Phase...
How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years — getting a Covid...
Institutions and billionaire investors worldwide are already well ahead of the game when it comes to AI-powered investing, extensively using, customizing, and developing it to bulk...
BELLEVUE, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Truveta, the company with a mission of saving lives with data, welcomes its first member from the life science industry to its...
Before successful weight loss treatments such as Wegovy and Ozempic, the pharmaceutical path to treating obesity was strewn with failures dating back decades.
(Updated - December 1, 2023 12:06 PM EST) Investing.com -- Main U.S. indexes climbed following a speech from Fed Chair Jerome Powell. Powell said the Fed needs to move carefully...
By Manas Mishra and Michael Erman (Reuters) -Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after...
Benzinga - by Vandana Singh, Benzinga Editor. Pfizer Inc (NYSE: PFE) reported topline data from the Phase 2b trial investigating its oral weight loss drug Glucagon-like peptide-1...